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It has been shown that 36 nm Nano-Se has lower toxicity than selenite or selenomethionine, but 
these forms of selenium (Se) all possess similar ability to increase selenoenzyme levels. The size 
of nanoparticles plays an important role in their biological activity: as expected, 5–200 nm Nano-
Se can directly scavenge free radicals in vitro in a size-dependent fashion. However, in Se-
deficient cells and Se-deficient mice, the size effect of Nano-Se on increasing selenoenzymes 
and liver Se disappears unexpectedly. We hypothesize that under conditions of Se deficiency, the 
avidity of Se uptake mechanisms may be increased to maintain the biosynthesis of 
selenoenzymes, which are fundamental for redox homeostasis. This increased avidity may 
override the potential advantage of small size Nano-Se seen under Se-replete conditions, thereby 
eliminating the size effect. Once selenoenzymes have been saturated, Se uptake mechanisms may 
downregulate; accordingly, the size effect of Nano-Se can then reappear. To test this hypothesis, 
Se-deficient mice were administered either 36 or 90 nm Nano-Se at supranutritional doses, in 
both a short-term model and a single-dose model. Under these conditions, Nano-Se showed a 
size effect on Se accumulation and glutathione S-transferase (GST) activity. A size effect of 
Nano-Se was found in 15 out of 18 total comparisons between sizes at the same dose and time in 
the two models. Furthermore, the magnitude of the size effect was more prominent on Se 
accumulation than on GST activity. GST is strictly regulated by transcriptional and translational 
mechanisms, so its increase in activity normally does not exceed 3-fold. In contrast, the 
homeostasis of Se accumulation is not as tightly controlled. In the present experiments, GST 
activity had reached or was approaching saturation, but liver Se was far below saturation. 
Therefore, our results strongly suggest that the saturation profile of the tested biomarker has an 
impact on the size effect of Nano-Se. Since both GST and small molecular weight 
selenocompounds accumulated in vivo are important intermediates for chemoprevention by Se, 
our results also suggest that Nano-Se should be most effective as a chemopreventive agent at 
smaller particle size. 
 






It is well known that elemental selenium (Se) at micrometer size and above is black, vitreous, 
insoluble and biologically inert [1]. Elemental Se nanospheres (300 nm) have been found in 
certain anaerobic bacteria [2], [3]. Furthermore, it has been reported that the presence of protein 
can control the aggregation of elemental Se atoms to form elemental Se nanoparticles (Nano-
Se) [1], [4]. Various sizes of Nano-Se can be obtained by changing the concentration of bovine 
serum albumin (BSA). Generally, the higher the BSA concentration, the smaller the resulting 
Nano-Se particle size [5]. It has been shown that 36 nm Nano-Se is as efficient as selenite or 
selenomethionine in regard to bioavailability, e.g., in terms of ability to increase glutathione 
peroxidase (GPx) and thioredoxin reductase (TrxR) enzyme activities [1], [6]. Moreover, 36 nm 
Nano-Se possesses significantly lower toxicity as compared to selenite or 
selenomethionine [1], [5], [6], [7], [8]. 
 
The size of nanoparticles plays an important role in their biological activity. Generally, smaller 
sized nanoparticle are more active than those of larger size [5], [9], [10]. For example, smaller 
sized regular nanoparticles exert a stronger cytotoxic effect on endothelial cells than those of 
larger size [11], and smaller sized chitosan nanoparticles have more potent tumor inhibitory 
effects than those of larger size [12]. As to elemental Se, some properties are indeed dependent 
on its size. Above micrometer size, it is biologically inert [1]. In contrast, subnano particles of 
elemental Se have robust cytotoxicity to leukemia cells [4]. It has been reported that Nano-Se has 
a size effect on redox reactivity [13], and Nano-Se in the range of 5–200 nm has a size-
dependent effect in directly scavenging various free radicals in vitro, such as 1,1-diphenyl-2-
picryhydrazyl (DPPH) and the superoxide anion [14]. Contrary to the phenomenon in vitro, the 
same set of Nano-Se no longer has a size effect on enhancing the activity of GPx, TrxR and 
phospholipid hydroperoxide glutathione peroxidase (PHGPx) in Se-deficient HepG2 cells; it also 
has no size effect on increasing the activity of GPx and TrxR in liver, as well as liver Se levels, 
at doses close to the nutritional level (70 g Se/kg for 7 days) in Se-deficient mice [5]. We 
speculated that the disappearance of size effect on selenoenzymes may be due to intrinsic 
mechanisms that counteract or override the potential advantage of smaller sized Nano-Se. It is 
known that selenoenzymes are fundamental for redox homeostasis. GPx1 knockout mice are 
more vulnerable to oxidative stress [15], [16], GPx1/GPx2-double-knockout mice have a trend to 
develop cancer [17], knockout of PHGPx causes early embryonic lethality [18], [19], and 
knockout of TrxR results in embryonic lethality [19]. Therefore, when cells are in a Se deficient 
state, the avidity of Se uptake mechanisms may be increased to maintain the biosynthesis of 
selenoenzymes. Under the circumstance of Se deficiency, cells may upregulate one or more 
effective pathways for Se uptake, leading to the disappearance of the size effect of Nano-Se on 
selenoenzyme synthesis. 
 
Se at supranutritional doses exerts a chemopreventive effect via multiple mechanisms, such as 
the induction of glutathione S-transferase (GST) for detoxifying electrophilic compounds 
generated during xenobiotic metabolism [20], [21], [22], [23], [24] and the accumulation of 
small molecular weight selenocompounds that can exert cytotoxic effects [24], [25], [26]. 
Although highly effective in chemoprevention, the supranutritional doses of Se which are 10-
fold more than the normal physiological requirement [6] are in fact approaching the toxic level 
of Se [24], [27], [28]. Under this circumstance, the cells are less likely to still have the demand to 
actively absorb Se for the biosynthesis of selenoenzymes, because they have been 
saturated [29], [30]. In contrast, they may switch to a strategy to prevent the entry of Se, to avoid 
potential toxicity. We speculated that the potential advantage and superior absorption 
characteristics of small size Nano-Se would reappear under such conditions. To test this 
hypothesis, the present study investigated the size effect of Nano-Se at supranutritional dose 
levels on Se accumulation and GST activity in mice. 
 
2. Materials and methods 
 
2.1. Preparation of Nano-Se 
 
Different sizes of Nano-Se were prepared by adding varying amount of BSA to a redox system 
of selenite and glutathione (GSH) as previously reported [1], [14]. 
 
2.2. Animals and treatments 
 
2.2.1. Se-deficient mice 
 
All mice were purchased from the animal center in Anhui Medical University. Mice and their 
offspring in the animal center had been continuously fed with a Se-deficient diet (<0.02 μg Se/g 
diet) for more than one generation to deplete selenium. 
 
2.2.2. Short-term model 
 
Forty mice were randomly divided into five groups: the control group was treated with saline; 
the other groups were administered either 36 nm or 90 nm of Nano-Se at the doses of 0.5 or 2 mg 
Se/kg for 7 days. 
 
2.2.3. Single-dose model 
 
Forty five mice were randomly divided into nine groups: the control was supplied with saline; 
the other groups were administered a single dose of either 36 or 90 nm Nano-Se at 5 or 10 mg 
Se/kg and sacrificed after 24 or 72 h. 
 
All the animals were housed at 22 ± 2 °C and 55% humidity, given a constant 12 h day/12 h 
night diurnal cycle, and received humane care in accordance with the guidelines of University of 




Blood was centrifuged at 3000g for 10 min to isolate plasma, and then stored at −30 °C. Livers 
were excised immediately and rinsed in ice cold saline, then stored at −30 °C. Livers were 
homogenized with ice cold saline and centrifuged at 15,000g at 4 °C for 15 min. The resulting 
supernatants were used for the determination of GPx and GST activities. Protein levels were 
determined by the Bradford method with BSA as standard. GPx was assayed by the method of 
Rotruck et al. [31]. GPx activity was expressed as units/mg protein or units/ml plasma; one unit 
of the activity was calculated in terms of 1 μmol of glutathione oxidized/min. The GST activity 
was expressed as units/min/mg protein; one unit of the activity was calculated in terms of nmoles 
1-chloro-2,4-dinitrobenzene (CDNB) changed [32]. Se was assayed by the diamino–naphthalene 
method [33]: first, the sample was digested using the mixture of nitric acid and perchloric acid at 
the molar ratio of 3:1, then reacted with diamino–naphthalene in 60 °C for 30 min, then finally 
extracted with hexamethylene. The fluorescence intensity excited at 378 nm and recorded at 
512 nm was used for calculating Se based on the fluorescence intensity of standard 
concentrations of Se. 
 
2.4. Statistical analysis 
 
Data are presented as the means ± SD. The differences between the groups, which were 
considered significant at p-values of less than 0.05, were determined by using one-way analysis 
of variance (ANOVA) test. 
 
3. Results and discussions 
 
Previous studies showed that different sizes of Nano-Se could be prepared by changing the BSA 
concentration used in the preparation [5], [14]. Generally, the higher the BSA concentration, the 
smaller the resulting Nano-Se particle size [5]. We prepared two sizes of Nano-Se by adding 
different concentrations of BSA into the redox system containing selenite and GSH. 
Transmission electron microscopy (TEM) images are shown in Fig. 1. Both the forms of Nano-
Se present as spherical particles, with diameters of 36 ± 6 nm (Fig. 1a) and 90 ± 8 nm (Fig. 1b), 
respectively. At the same concentration of Se, the number of particles for 36 nm Nano-Se is 
roughly one order of magnitude more than that for 90 nm Nano-Se, which is similar to the result 
reported by Chen et al. [34]. 
 
The primary purpose of this study was to find whether Nano-Se has a size effect at 
supranutritional dose levels. Treating mice with Se compounds at supranutritional doses (0.5–
1.1 mg Se/kg) for 7 days is a short-term experimental model for assessing the chemopreventive 
potency of Se [23], [24]. Thus, the mice were administered Nano-Se at doses of 0.5 or 2.0 mg 
Se/kg for seven consecutive days. Blood Se (Fig. 2a) and liver GST activity (Fig. 3) were size-
dependently increased by Nano-Se at both doses. Liver Se (Fig. 2b) was size-dependently 
increased by Nano-Se at 2 mg Se/kg. 
 
The short-term model gave a cumulative result. However, utilization of Se comprises a series of 
dynamic processess, for example, Se concentration in liver rapidly increases and then gradually 
decreases [35]. To see if a size effect exists during these dynamic processes, mice were treated 
with a single dose of Nano-Se at 5 or 10 mg Se/kg. At 24 h, blood Se and liver Se (Fig. 4a and b) 
were size-dependently increased by Nano-Se. At 72 h, blood Se (Fig. 4a), liver Se (Fig. 4b) and 
liver GST activity (Fig. 5) were size-dependently increased by Nano-Se. 
 
 
Fig. 1. Transmission electron microscopy images of Nano-Se. (a) 36 nm; (b) 90 nm. The bar in 
each figure represents 110 nm. 
 
 
Fig. 2. Size effects of Nano-Se on Se accumulations. (a) Blood Se; (b) liver Se. Mice were 
administered Nano-Se at doses of either 0.5 or 2.0 mg Se/kg body weight for seven consecutive 
days (n = 8). The data are expressed as means ± SD. The statistical significance between sizes is 
marked on each column. 
 
 
Fig. 3. Size effects of Nano-Se on increasing liver GST activity. Mice were administered Nano-
Se at doses of either 0.5 or 2.0 mg Se/kg body weight for seven consecutive days (n = 8). The 
data are expressed as means ± SD. The statistical significance between sizes is marked on each 
column. 
 
Fig. 4. Size effects of Nano-Se on Se accumulations. (a) Blood Se; (b) liver Se. Mice were 
administered a single dose of Nano-Se at the level of either 5.0 or 10.0 mg Se/kg body weight 
(n = 5). The data are expressed as means ± SD. The statistical significance between sizes is 
marked on each column. 
 
 
Fig. 5. Size effects of Nano-Se on increasing liver GST activity. Mice were administered a single 
dose of Nano-Se at the level of either 5.0 or 10.0 mg Se/kg body weight (n = 5). The data are 
expressed as means ± SD. The statistical significance between sizes is marked on each column. 
 
In summary, the size effect of Nano-Se was verified in two models in the present study. In the 
short-term model and the single-dose model, each model examined two doses of Nano-Se and 
two biological parameters (Se accumulation and GST activity); moreover, the latter model 
included two time points. There were a total of 18 comparisons between sizes at the same dose 
and time. The size effect of Nano-Se was observed in 15 of them. These results are summarized 
in Table 1, from which it can be observed that the potency of the size effect of Nano-Se on the 
tested biomarkers is different, the rank being as follows: blood Se > liver Se > liver GST. 
 
Table 1. Ratio of differences in Se biomarkers between two particle sizes at the same time and 
dose  
Short-term model Single-dose model Mean ± SD 
7 days 7 days 24 h 24 h 72 h 72 h 
0.5 mg/kg 2 mg/kg 5 mg/kg 10 mg/kg 5 mg/kg 10 mg/kg 
Blood-Se 1.32a 1.60b 1.66c 1.81b 2.41c 2.74a 1.92 ± 0.54 
Liver-Se 1.06 1.30a 1.94a 1.48c 1.21c 1.39c 1.40 ± 0.30 
Liver-GST 1.21c 1.14c 1.06 0.94 1.22c 1.42b 1.17 ± 0.16 
a p < 0.001. 
b p < 0.01. 
c p < 0.05 indicated significant different between sizes. 
 
It has been suggested that the rank of the size effects of Nano-Se on the tested biomarkers may 
be associated with the different saturation profiles of the tested biomarkers. Our previous study 
showed that 36 nm Nano-Se at the dose of 5 mg Se/kg for 7 days increased liver Se to a level of 
10 μg Se/g [6]. In the present study, liver Se was increased to 2.1 μg Se/g in the short-term 
model and increased to 3.6 μg Se/g in the single-dose model by 36 nm Nano-Se, both of which 
are far below 10 μg Se/g, demonstrating that liver Se in the present experiments did not approach 
saturation. Although GST could be modulated by higher dose of Se [22], [23], [24], its synthesis 
undergoes strict control at the transcriptional and translational levels [23], [24], [36]. Normally, 
its maximum activity is approximately 2–3-fold higher than the control [22], [37], [38]. In the 
present work, GST activities were maximally increased to 1.8- and 2.4-fold higher than the 
control in the short-term model and the single-dose model, respectively. The results demonstrate 
that GST had reached or was approaching saturation. All these data indicate that liver GST is 
more easily saturated than liver Se, leading to compromised size effect on GST as compared with 
liver Se (Table 1). Thus, the saturation profile of a tested biomarker has an obvious impact on the 
size effect of Nano-Se on the biomarker. 
 
It is generally accepted that when a biomarker is approaching its saturation status, the dose-
dependent response will compromise or disappear, and verse versa. Thus, the intensity of the 
dose dependency of a biomarker can be used to estimate the saturation status of the biomarker. 
For this reason, we calculated the ratio of Se biomarkers between two doses at the same time and 
particle size (Table 2). The sequence of dose dependency of the biomarkers is as follows: blood 
Se > liver Se > liver GST. This sequence indicates that, within the dose range used herein, liver 
Se is more difficult to saturate than GST, a result that is consistent with the deduction described 
above. Also this sequence implies that blood Se is the hardest to saturate among the three 
biomarkers. Since saturation profile has an obvious impact on size effect of Nano-Se, the size 
effect of Nano-Se on blood Se ought to be more marked compared with liver Se or liver GST. 
Indeed, the size effect of Nano-Se on blood Se is the most prominent among the three 
biomarkers (Table 1). These observations consistently support the conclusion that the saturation 
profile of the tested biomarker has an obvious impact on the size effect of Nano-Se. 
 
Table 2. Ratio of differences in Se biomarkers between two doses at the same time and particle 
size  
Short-term model Single-dose model Mean ± SD 
7 days 7 days 24 h 24 h 72 h 72 h 
36 nm 90 nm 36 nm 90 nm 36 nm 90 nm 
Blood-Se 1.88a 1.60a 2.62b 2.40a 2.07c 1.82b 2.06 ± 0.38 
Liver-Se 1.72a 1.40a 1.32c 1.73c 1.21c 1.05 1.41 ± 0.27 
Liver-GST 1.41a 1.33a 0.95 1.07 1.25c 1.08 1.18 ± 0.18 
a p < 0.001. 
b p < 0.01. 
c p < 0.05 indicated significant different between doses. 
 
 
Fig. 6. The effect of two sizes of Nano-Se on GPx activity. (a) GPx in liver in a short-term 
model. (b) GPx in plasma in a short-term model. (c) GPx in liver in a single-dose model. (d) GPx 
in liver in a single-dose model. Mice in the short-term model were administered Nano-Se at the 
doses of either 0.5 or 2.0 mg Se/kg body weight for seven consecutive days (n = 8); Mice in the 
single-dose model were administrated with a single dose of Nano-Se at the level of either 5.0 or 
10.0 mg Se/kg body weight (n = 5). The data are expressed as means ± SD. 
 
To further support this conclusion, we compared the size effect of Nano-Se on GPx activity in 
the present experimental models. It is well known that GPx activity can be saturated at 
nutritional levels [6], [39] and that further supplementation with supranutritional levels of Se 
does not further increase its activity [24], [29], [30], suggesting GPx is an easily saturated 
biomarker compared to Se accumulation and GST. According to the conclusion that the 
saturation profile of the tested biomarker has an impact on the size effect of Nano-Se, the size 
effect of Nano-Se on GPx ought to be less prominent as compared with liver GST or liver Se or 
blood Se. As expected, as shown in Fig. 6, none of the total 12 comparisons related to GPx 
activity between two sizes showed a size effect. 
 
The present study not only shows that Nano-Se has a size effect in mice, but also establishes that 
the saturation profile of the tested biomarker has an obvious impact on the size effect. Since the 
levels of small molecular weight selenocompounds accumulated in vivo and GST are size-
dependent, and these are important intermediates for the chemoprevention of Se [6], [22], [26], 
our results also suggest that Nano-Se should be most effective as a chemopreventive agent at 




ANOVA one-way analysis of variance 
BSA bovine serum albumin 
CDNB 1-chloro-2,4-dinitrobenzene 
DPPH 1,1-diphenyl-2-picryhydrazyl 
Nano-Se elemental Se nanoparticles 
GPx glutathione peroxidase 
GSH glutathione 
GST glutathione S-transferase 
PHGPx phospholipid hydroperoxide glutathione peroxidase 
Se selenium 
TEM transmission electron microscopy 
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